Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
respiratory syncytial virus vaccine + tetanus diphtheria and acellular pertussis vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine regimen for **preventing respiratory syncytial virus (RSV) illness, tetanus, diphtheria, and pertussis** using concurrent administration of a stabilized prefusion F subunit RSV vaccine (such as ABRYSVO) and a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap, such as Adacel or Boostrix). The RSV vaccine works by inducing neutralizing antibody responses to the RSV F protein, covering RSV-A and RSV-B. The Tdap vaccine induces immune responses against tetanus toxin, diphtheria toxin, and pertussis virulence antigens (pertussis toxin, filamentous hemagglutinin, pertactin). This regimen is under investigation mainly for maternal immunization to provide neonatal protection via antibody transfer. In clinical studies, **concomitant administration was safe and delivered noninferior immune responses for RSV, tetanus, and diphtheria; immune response to pertussis antigen was lower compared to Tdap alone**[1][2]. Principal companies developing or manufacturing individual vaccines are Pfizer (for RSVpreF/ABRYSVO), GlaxoSmithKline (Boostrix), and Sanofi (Adacel).
- Brand names
- ABRYSVO + AdacelABRYSVO + Boostrix
- Other names
- respiratory syncytial virus stabilized prefusion F subunit vaccine + tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccineRSVpreF + TdapRSV vaccine + Tdap vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)PRN (Pertactin)Diphtheria toxinFHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on respiratory syncytial virus vaccine + tetanus diphtheria and acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on respiratory syncytial virus vaccine + tetanus diphtheria and acellular pertussis vaccine.